Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Language | Translation |
---|---|
English | Severe mental and behavioural disorders associated with the puerperium, not elsewhere classified |
French | Troubles mentaux et du comportement sévères associés à la puerpéralité, non classés ailleurs |
Level | Code | Title | |
---|---|---|---|
1 | V | Mental and behavioural disorders | |
2 | F50-F59 | Behavioural syndromes associated with physiological disturbances and physical factors | |
3 | F53 | Mental and behavioural disorders associated with the puerperium, not elsewhere classified | |
4 | F53.1 | Severe mental and behavioural disorders associated with the puerperium, not elsewhere classified |
Active Ingredient | Description | |
---|---|---|
Penfluridol |
|
|
Pimozide |
Pimozide is an orally active neuroleptic drug which blocks central dopaminergic receptors. Pimozide antagonises many of the actions of amphetamine and apomorphine. |
|
Pipamperone |
|
|
Sulpiride |
Sulpiride is a member of the group of substituted benzamides, which are structurally distinct from the phenothiazines, butyrophenones and thioxanthenes. One of the characteristics of sulpiride is its bimodal activity, as it has both antidepressant and neuroleptic properties. Schizophrenia characterised by a lack of social contact can benefit strikingly. |
|
Tiapride |
Tiapride is an atypical neuroleptic which exhibits selectivity in in-vitro studies for D2 and D3 dopamine subtype receptors without any affinity for subtype receptors of the principal central neurotransmitters (including serotonin, noradrenaline and histamine). |
|
Trifluoperazine |
Trifluoperazine is one of the phenothiazine class of compounds and as such has many pharmacodynamic effects which relate to its therapeutic actions and side effects. The most notable action of phenothiazines is antagonism at dopamine receptors in the CNS. |